Aleš Obr

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca et al. · The Lancet Oncology · 2020 · 519 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano, Jon Salmanton‐García, Francesco Marchesi et al. · Journal of Hematology & Oncology · 2021 · 318 citations · Full text

Medicine, Hematology, Infectious Diseases +13

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell, Kami J. Maddocks, Eva González‐Barca et al. · Haematologica · 2021 · 140 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy

Diana Maláriková, Adéla Berková, Aleš Obr et al. · Cancers · 2020 · 49 citations · Full text

Medicine, Hematology, Oncology +17

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Arne Kolstad, Tim Illidge, Nils Bolstad et al. · Blood Advances · 2020 · 44 citations · Full text

Medicine, Hematology, Oncology +14